Document is current
Any future updates will be listed below
-
Authors
Nguyen, Hoang Oanh
Salvi, Valentina
Tiberio, Laura
Facchinetti, Fabrizio
Govoni, Mirco
Villetti, Gino
Civelli, Maurizio
Barbazza, Ilaria
Gaudenzi, Carolina
Passari, Mauro
Schioppa, Tiziana
Sozio, Francesca
Del Prete, Annalisa
Sozzani, Silvano
Bosisio, Daniela
-
Funding
Funding for this research was provided by:
Ministero della Salute (Bando Ricerca COVID-2020-12371735)
Ministero dell’Istruzione, dell’Università e della Ricerca (MUR-PRIN 20178ALPCM_005)
Università degli Studi di Brescia (Fondi Locali 2019, 2020)
Chiesi Farmaceutici
- License Information
-
More Information
Article History
Received: 26 March 2022
Accepted: 20 April 2022
First Online: 10 May 2022
Declarations
:
: The clinical trial EudraCT (registration ID number: 2015-005550-35) is registered on ClinicalTrials.gov (). The study was approved by independent ethics committees for each institution. All patients provided written informed consent prior to study start. The results were published on Respiratory Research ().
: Not applicable.
: This study also received funding from Chiesi Farmaceutici S.p.A., which is currently sponsoring clinical development of tanimilast. The funder had the following involvement with the study: provided tanimilast and instructions for its usage, contributed to general research planning and to manuscript review and editing, approved decision to publish. F.F., G.V., M.G. and M.C. also disclose that they are employees of Chiesi Farmaceutici S.p.A. that do not hold Chiesi Farmaceutici S.p.A. stocks or equity shares.
